Pharmacy-based screening to detect persons at elevated risk of type 2 diabetes: a cost-utility analysis

被引:5
作者
Jalkanen, Kari [1 ]
Aarnio, Emma [1 ]
Lavikainen, Piia [1 ]
Lindstrom, Jaana [2 ]
Peltonen, Markku [2 ]
Laatikainen, Tiina [3 ,4 ,5 ]
Martikainen, Janne [1 ]
机构
[1] Univ Eastern Finland, Sch Pharm, Fac Hlth Sci, POB 1627, Kuopio 70211, Finland
[2] Finnish Inst Hlth & Welf, Dept Publ Hlth Solut, POB 30, Helsinki 00271, Finland
[3] Univ Eastern Finland, Fac Med, Inst Publ Hlth & Clin Nutr, POB 16277, Kuopio 70211, Finland
[4] Finnish Inst Hlth & Welf, Chron Dis Epidemiol & Prevent Unit, Helsinki, Finland
[5] Joint Municipal Author North Karelia Hlth & Socia, Joensuu, Finland
基金
芬兰科学院;
关键词
Type; 2; diabetes; Pharmacy; Markov model; Cost effectiveness analysis; LIFE-STYLE INTERVENTIONS; FOLLOW-UP; PREVENTION; VALUES; IMPACT; CARE;
D O I
10.1186/s12913-021-06948-6
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Early identification of people at elevated risk of type 2 diabetes (T2D) is an important step in preventing or delaying its onset. Pharmacies can serve as a significant channel to reach these people. This study aimed to assess the potential health economic impact of screening and recruitment services in pharmacies in referring people to preventive interventions. Methods A decision analytic model was constructed to perform a cost-utility analysis of the expected national health economic consequences (in terms of costs and quality-adjusted life years, QALYs) of a hypothetical pharmacy-based service where people screened and recruited through pharmacies would participate in a digital lifestyle program. Cost-effectiveness was considered in terms of net monetary benefit (NMB). In addition, social return on investment (SROI) was calculated as the ratio of the intervention and recruitment costs and the net present value of expected savings. Payback time was the time taken to reach the break-even point in savings. In the base scenario, a 20-year time horizon was applied. Probabilistic and deterministic sensitivity analyses were applied to study robustness of the results. Results In the base scenario, the expected savings from the pharmacy-based screening and recruitment among the reached target cohort were 255.3 meuro (95% CI - 185.2 meuro to 717.2 meuro) in pharmacy visiting population meaning 1412euro (95% CI - 1024euro to 3967euro) expected savings per person. Additionally, 7032 QALYs (95% CI - 1344 to 16,143) were gained on the population level. The intervention had an NMB of 3358euro (95% CI - 1397euro to 8431euro) using a cost-effectiveness threshold of 50,000 euro/QALY. The initial costs were 122.2 meuro with an SROI of 2.09euro (95% CI - 1.52euro to 5.88euro). The expected payback time was 10 and 8 years for women and men, respectively. Results were most sensitive for changes in effectiveness of the intervention and selected discount rate. Conclusions T2D screening and recruitment to prevention programs conducted via pharmacies was a dominant option providing both cost savings and QALY gains. The highest savings can be potentially reached by targeting recruitment at men at elevated risk of T2D.
引用
收藏
页数:11
相关论文
共 57 条
  • [1] [Anonymous], 2016, INT DIABETES FEDERAT, V8th, DOI [10.1016/S0140-6736(16)31679-8, DOI 10.1016/S0140-6736(16)31679-8]
  • [2] Arffman M, 2020, INCIDENCE PREVALENCE
  • [3] Association of Finnish Pharmacies, 2017, ANN REV 2017
  • [4] Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data
    Bagust, A
    Beale, S
    [J]. HEALTH ECONOMICS, 2005, 14 (03) : 217 - 230
  • [5] Review of Utility Values for Economic Modeling in Type 2 Diabetes
    Beaudet, Amelie
    Clegg, John
    Thuresson, Per-Olof
    Lloyd, Adam
    McEwan, Phil
    [J]. VALUE IN HEALTH, 2014, 17 (04) : 462 - 470
  • [6] Diabetes Prevention and Weight Loss with a Fully Automated Behavioral Intervention by Email, Web, and Mobile Phone: A Randomized Controlled Trial Among Persons with Prediabetes
    Block, Gladys
    Azar, Kristen M. J.
    Romanelli, Robert J.
    Block, Torin J.
    Hopkins, Donald
    Carpenter, Heather A.
    Dolginsky, Marina S.
    Hudes, Mark L.
    Palaniappan, Latha P.
    Block, Clifford H.
    [J]. JOURNAL OF MEDICAL INTERNET RESEARCH, 2015, 17 (10)
  • [7] Borodulin K, 2013, NATL FINRISKI 2012 S
  • [8] 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study
    Bray, G. A.
    Chatellier, A.
    Duncan, C.
    Greenway, F. L.
    Levy, E.
    Ryan, D. H.
    Polonsky, K. S.
    Tobian, J.
    Ehrmann, D.
    Matulik, M. J.
    Clark, B.
    Czech, K.
    DeSandre, C.
    Hilbrich, R.
    McNabb, W.
    Semenske, A. R.
    Goldstein, B. J.
    Smith, K. A.
    Wildman, W.
    Pepe, C.
    Goldberg, R. B.
    Calles, J.
    Ojito, J.
    Castillo-Florez, S.
    Florez, H. J.
    Giannella, A.
    Lara, O.
    Veciana, B.
    Haffner, S. M.
    Montez, M. G.
    Lorenzo, C.
    Martinez, A.
    Hamman, R. F.
    Testaverde, L.
    Bouffard, A.
    Dabelea, D.
    Jenkins, T.
    Lenz, D.
    Perreault, L.
    Price, D. W.
    Steinke, S. C.
    Horton, E. S.
    Poirier, C. S.
    Swift, K.
    Caballero, E.
    Jackson, S. D.
    Lambert, L.
    Lawton, K. E.
    Ledbury, S.
    Kahn, S. E.
    [J]. LANCET, 2009, 374 (9702) : 1677 - 1686
  • [9] Briggs A, 2006, DECISION MODELLING H
  • [10] Probabilistic analysis of cost-effectiveness models: Choosing between treatment strategies for gastroesophageal reflux disease
    Briggs, AH
    Goeree, R
    Blackhouse, G
    O'Brien, BJ
    [J]. MEDICAL DECISION MAKING, 2002, 22 (04) : 290 - 308